Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 261

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

Open access
Henriksen, Tenna Vesterman, Tarazona, Noelia, Frydendahl, Amanda, Reinert, Thomas, Gimeno-Valiente, Francisco, Carbonell-Asins, Juan Antonio, Sharma, Shruti, Renner, Derrick, Hafez, Dina, Roda, Desamparados, Huerta, Marisol, Roselló, Susana, Madsen, Anders Husted, Løve, Uffe S., Andersen, Per Vadgaard, Thorlacius-Ussing, Ole, Iversen, Lene Hjerrild, Gotschalck, Kåre Andersson, Sethi, Himanshu, Aleshin, Alexey, Cervantes, Andres, Andersen, Claus Lindbjerg · 2022 · Clinical Cancer Research

Abstract

Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. Experimental Design: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic single-nucleotide variants were profiled using multiplex-PCR, next-generation sequencing. Results: Detection of ctDNA was a strong recurrence predictor postoperatively [HR = 7.0; 95% confidence interval (CI), 3.7–13.5; P < 0.001] and directly after ACT (HR = 50.76; 95% CI, 15.4–167; P < 0.001). The recurrence rate of postoperative ctDNA-positive patients treated with ACT was 80% (16/20). Only patients who cleared ctDNA permanently during ACT did not relapse. Serial ctDNA assessment after the end of treatment was similarly predictive of recurrence (HR = 50.80; 95% CI, 14.9–172; P < 0.001), and revealed two distinct rates of exponential ctDNA growth, slow (25% ctDNA-increase/month) and fast (143% ctDNA-increase/month; P < 0.001). The ctDNA growth rate was prognostic of survival (HR = 2.7; 95% CI, 1.1–6.7; P = 0.039). Serial ctDNA analysis every 3 months detected recurrence with a median lead-time of 9.8 months compared with standard-of-care computed tomography. Conclusions: Serial postoperative ctDNA analysis has a strong prognostic value and enables tumor growth rate assessment. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding decision-making. See related commentary by Morris and George, p. 438

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-2404

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 261

Metadata

Authors
Henriksen, T. V., Tarazona, N., Frydendahl, A., Reinert, T., Gimeno-Valiente, F., Carbonell-Asins, J. A., Sharma, S., Renner, D., Hafez, D., Roda, D., Huerta, M., Roselló, S., Madsen, A. H., Løve, U. S., Andersen, P. V., Thorlacius-Ussing, O., Iversen, L. H., Gotschalck, K. A., Sethi, H., Aleshin, A., Cervantes, A., & Andersen, C. L.
Venue
Clinical Cancer Research
Published
2021-10-01
Volume
28
Issue
3
Pages
507-517
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3203274060
Cited by
261
References
27
FWCI
12.62
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-2404
The paper
Henriksen, T. V., Tarazona, N., Frydendahl, A., Reinert, T., Gimeno-Valiente, F., Carbonell-Asins, J. A., Sharma, S., Renner, D., Hafez, D., Roda, D., Huerta, M., Roselló, S., Madsen, A. H., Løve, U. S., Andersen, P. V., Thorlacius-Ussing, O., Iversen, L. H., Gotschalck, K. A., Sethi, H., . . . Andersen, C. L. (2022). Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-2404

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.